Skip to main content
Fig. 1 | Antimicrobial Resistance & Infection Control

Fig. 1

From: Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients

Fig. 1

In vitro potency of anti-pseudomonal cephalosporins against carbapenem-resistant P. aeruginosa (CR-PA) from ICU and non-ICU settings in a global surveillance program. ICU: n = 275; MIC50/90 (mg/L) for Ceftazidime (32/>64), cefepime (16/>64), ceftolozane/tazobactam (2/>64), ceftazidime/avibactam (4/64). Non-ICU: n = 397; MIC50/90 (mg/L) for Ceftazidime (16/>64), cefepime (8/>64), ceftolozane/tazobactam (1/>64), ceftazidime/avibactam (4/64)

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us